跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ONTRUZANT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ONTRUZANT
Authorized
STANDARD
ONTRUZANT
Samsung Bioepis Co., Ltd.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
18bce5bcac70db11
Company
Samsung Bioepis Co., Ltd.
Type
Standard
Approval Details
Approval Id
18bce5bcac70db11
Drug Approval Canada Name
ONTRUZANT
Product Name
ONTRUZANT
Status
Marketed
Status Date
2022-07-20
Original Market Date
2022-07-20
Din
02524325
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FD01 TRASTUZUMAB
Atc Name
l 01 fd 01
Aig Number
0154252001
Company Name
Samsung Bioepis Co., Ltd.
Company Address
76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path
/organization/samsung-bioepis-co-ltd
Company Information
Pharmaceutical Company Name
Samsung Bioepis Co., Ltd.
Country Name
South Korea
Province Name
Incheon
City Name
incheon,incheon,country_kr
Address
76 Songdogyoyuk-ro, Yeonsu-gu
Website
http://www.samsungbioepis.com
Active Ingredients
TRASTUZUMAB
440 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
18bce5bcac70db11
Type
Standard
Back to Health Canada Approvals